Skip to main content
SpringerLink
Log in

Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Shomali W, Colucci P, George TI, Kiladjian JJ, Langford C, Patel JL, Reiter A, Vannucchi AM, Gotlib J (2023) Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. Leukemia 37(5):981–987. https://doi.org/10.1038/s41375-023-01859-3

    Article  PubMed  PubMed Central  Google Scholar 

  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544

    Article  PubMed  CAS  Google Scholar 

  3. Yu J, Canalis E (2020) Notch and the regulation of osteoclast differentiation and function. Bone 138:115474. https://doi.org/10.1016/j.bone.2020.115474

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Kurotaki D, Yoshida H, Tamura T (2020) Epigenetic and transcriptional regulation of osteoclast differentiation. Bone 138:115471. https://doi.org/10.1016/j.bone.2020.115471

    Article  PubMed  CAS  Google Scholar 

  5. McGregor AK, Greystoke B, Wood K, Bedwell C, Oakes R (2016) Pathological fracture due to lytic lesion caused by a myeloid neoplasm with FIP1L1-PDGFRA. Br J Haematol 174(5):660. https://doi.org/10.1111/bjh.14203

    Article  PubMed  Google Scholar 

  6. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18(4):734–742. https://doi.org/10.1038/sj.leu.2403313

    Article  PubMed  CAS  Google Scholar 

  7. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Muller MC, Beneke H, Muller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Muller-Hermelink K et al (2007) Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 21(6):1183–1188. https://doi.org/10.1038/sj.leu.2404662

    Article  PubMed  CAS  Google Scholar 

  8. Soung do Y, Kalinowski J, Baniwal SK, Jacome-Galarza CE, Frenkel B, Lorenzo J, Drissi H (2014) Runx1-mediated regulation of osteoclast differentiation and function. Mol Endocrinol 28 (4):546-553. https://doi.org/10.1210/me.2013-1305

  9. Paglia DN, Yang X, Kalinowski J, Jastrzebski S, Drissi H, Lorenzo J (2016) Runx1 regulates myeloid precursor differentiation into osteoclasts without affecting differentiation into antigen presenting or phagocytic cells in both males and females. Endocrinology 157(8):3058–3069. https://doi.org/10.1210/en.2015-2037

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. McDonald MM, Kim AS, Mulholland BS, Rauner M (2021) New insights into osteoclast biology. JBMR Plus 5(9):e10539. https://doi.org/10.1002/jbm4.10539

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We thank all members of the Zhejiang Key Laboratory of Diagnosis and Treatment for Hematologic Malignancies for providing supports for diagnosis. We also thank Prof. Dijiong Wu from The First Affiliated Hospital of Zhejiang Chinese Medical University for helping us finishing follow-up of this patient. The targeted-exome-sequencing was supported by Acornmed Company (Beijing, China), and the RNA-sequencing was supported by Annoroad Company (Beijing, China).

Funding

This study was funded by the Natural Science Foundation of Zhejiang Province (LY21H080003) and the National Natural Science Foundation of China (81800199).

Author information

Authors and Affiliations

  1. Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Rd, Hangzhou, 310003, Zhejiang, People’s Republic of China

    Yunfei Lv, Qing Ling, Shanshan Suo, Jinghan Wang, Shuqi Zhao, Hongyan Tong, Jie Jin, Xiang Zhang & Wenjuan Yu

  2. Zhejiang Provincial Key Laboratory of Hematologic Malignancy, Zhejiang University, Hangzhou, 310003, Zhejiang, People’s Republic of China

    Yunfei Lv, Qing Ling, Shanshan Suo, Jinghan Wang, Shuqi Zhao, Hongyan Tong, Jie Jin, Xiang Zhang & Wenjuan Yu

  3. Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, 310003, Zhejiang, People’s Republic of China

    Yunfei Lv, Qing Ling, Shanshan Suo, Jinghan Wang, Shuqi Zhao, Hongyan Tong, Jie Jin, Xiang Zhang & Wenjuan Yu

  4. Zhejiang University Cancer Center, Hangzhou, 310003, Zhejiang, People’s Republic of China

    Yunfei Lv, Qing Ling, Shanshan Suo, Jinghan Wang, Shuqi Zhao, Hongyan Tong, Jie Jin, Xiang Zhang & Wenjuan Yu

  5. Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Zhejiang, 310030, Hangzhou, China

    XingYun Yao & Xiaofei Gao

Authors
  1. Yunfei Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. XingYun Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shanshan Suo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jinghan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuqi Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaofei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hongyan Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jie Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wenjuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XZ designed the research. SS, JW, JJ, XZ, and WY managed this patient. SZ, XZ, and WY collected the data. YL, XY, QL, and XZ processed the data. YL and XZ wrote the manuscript. XG, HT, JJ, and WY provided advice for our study. All authors approved the manuscript.

Corresponding authors

Correspondence to Jie Jin, Xiang Zhang or Wenjuan Yu.

Ethics declarations

Ethics approval

This study was approved by the ethical review committees of the First Affiliated Hospital to Zhejiang University School of Medicine (IIT20220659A). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

Figure S1. Additional markers for immunohistochemistry of bone marrow tissue. (TIF 7567 kb)

ESM 2

Figure S2. GO and KEGG analysis for up-regulated genes in PD vs. CR samples. (A-D) GO biological process (A), GO molecular function (B), GO cellular component (C) and KEGG pathway (D) were enriched for up-regulated genes. (TIF 12092 kb)

ESM 3

Figure S3. GO and KEGG analysis for down-regulated genes in PD vs. CR samples. (A-D) GO biological process (A), GO molecular function (B), GO cellular component (C) and KEGG pathway (D) were enriched for down-regulated genes. (TIF 12312 kb)

ESM 4

Table S1. Gene fusions in PD sample. (PDF 94 kb)

ESM 5

Table S2. Gene fusions in CR sample. (PDF 77 kb)

ESM 6

Table S3. FPKM of PD and CR samples. (PDF 2993 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lv, Y., Yao, X., Ling, Q. et al. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report. Ann Hematol 103, 357–360 (2024). https://doi.org/10.1007/s00277-023-05485-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05485-y

Search

Navigation